The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
The M1/M2 spectrum and plasticity of malignant pleural effusion-macrophage in advanced lung cancer
Open accessAbstract
Background: Malignant pleural effusion (MPE)-macrophage (Mφ) of lung cancer patients within unique M1/M2 spectrum showed plasticity in M1–M2 transition. The M1/M2 features of MPE-Mφ and their significance to patient outcomes need to be clarified; furthermore, whether M1-repolarization could benefit treatment remains unclear. Methods: Total 147 stage-IV lung adenocarcinoma patients undergoing MPE drainage were enrolled for profiling and validation of their M1/M2 spectrum. In addition, the MPE-Mφ signature on overall patient survival was analyzed. The impact of the M1-polarization strategy of patient-derived MPE-Mφ on anti-cancer activity was examined. Results: We found that MPE-Mφ expressed both traditional M1 (HLA-DRA) and M2 (CD163) markers and showed a wide range of M1/M2 spectrum. Most of the MPE-Mφ displayed diverse PD-L1 expression patterns, while the low PD-L1 expression group was correlated with higher levels of IL-10. Among these markers, we identified a novel two-gene MPE-Mφ signature, IL-1β and TGF-β1, representing the M1/M2 tendency, which showed a strong predictive power in patient outcomes in our MPE-Mφ patient cohort (N = 60, p = 0.013) and The Cancer Genome Atlas Lung Adenocarcinoma dataset (N = 478, p < 0.0001). Significantly, β-glucan worked synergistically with IFN-γ to reverse the risk signature by repolarizing the MPE-Mφ toward the M1 pattern, enhancing anti-cancer activity. Conclusions: We identified MPE-Mφ on the M1/M2 spectrum and plasticity and described a two-gene M1/M2 signature that could predict the outcome of late-stage lung cancer patients. In addition, we found that “re-education” of these MPE-Mφ toward anti-cancer M1 macrophages using clinically applicable strategies may overcome tumor immune escape and benefit anti-cancer therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 M1 and M2 markers are heterogeneously expressed in malignant pleural effusion-macrophages (MPE-Mφ) of advanced lung cancer patients. a MPE-Mφ with the common macrophage marker CD68 were double-positive for the expression of M1 (HLA-DR) and M2 (CD163) markers. MPE-Mφ isolated using anti-CD14 microbeads were characterized by flow cytometry with CD14, CD68, HLA-DR, and CD163 staining. Gating was based on isotype control staining. b The coexpression of M1 (HLA-DR) and M2 markers (CD163) by MPE-Mφ from 16 MPE samples was further evaluated by flow cytometry. One point indicates 1 MPE-Mφ case. c Heatmap of M1, M2 and common macrophage marker gene expression for 60 MPE-Mφ and for reference M1 and M2 macrophages (NCBI GEO series GSE5099). The arrangement of the 60 MPE-Mφ subjects was based on survival days, and programmed death-ligand 1 (PD-L1) expression levels for patients are also shown under the survival days for the indicated patients. Sample numbers of MPE-Mφ (N = 60) or triplicates of reference macrophages are listed in the columns. Gene expression levels are illustrated in a color gradient; red/yellow indicates high expression, while blue indicates low expression, as shown in the right panel. The names of the genes in each cluster can be seen in the left panel. d The M1/M2 gene expression distribution for MPE-Mφ and reference M1 and M2 macrophages (GEO database, GSE5099). As described in “Materials and methods”, the sum expression for six M1 genes (x-axis, M1) and five M2 genes (y-axis, M2) was plotted in the figure. Black closed circles indicate the 60 MPE-Mφ samples, individually; blue closed triangles indicate the triplicate GSE5099 M1 macrophages; red closed triangles indicate the triplicate GSE5099 M2 macrophages. e The correlation between IL-10 and PD-L1 was studied by constructing a scatterplot with a linear regression. IL-10 gene expression negatively correlated with PD-L1 was selected from Supplementary Fig. 2 and a scatterplot with PD-L1 was generated using the R package ggpubr [44] and ggplot2 [45]. The correlation (R) and p value are shown in the figure. One dot indicates an individual subject (N = 59, no. 18 listed in c was ruled out because of undetectable PD-L1 expression). The red dotted line (PD-L1 = − 4) separates the MPE-Mφ samples into PD-L1 high (N = 37) and low populations (N = 22). f The gene expression of PD-L1 and IL-10 in PD-L1 high and low populations. The PD-L1 gene expression levels of the MPE-Mφ subjects were divided into PD-L1 high and low populations as shown in e. H, PD-L1 high population (N = 37); L, PD-L1 low population (N = 22). Data were expressed as the means ± SEM and compared using an unpaired t test; **p < 0.01, ****p < 0.0001. c–f Expression of MPE-Mφ genes was calculated and normalized as described in “Materials and methods”. g–h Kaplan–Meier estimates of NSCLC patient survival according to the indicated M1 (IL-1β) and M2 (TGF-β1) gene signature of their MPE-Mφ. g Kaplan–Meier curves of the overall survival (OS) for NSCLC according to the indicated M1 (IL-1β) and M2 (TGF-β1) gene signature of their MPE-Mφ. N = 60; log-rank test, p = 0.013. h Kaplan–Meier curves of OS for the Cancer Genome Atlas Lung Adenocarcinoma (TCGA-LUAD) data stratified by M1 (IL-1β) and M2 (TGF-β1) gene expression. N = 478; log-rank test, p < 0.0001](https://figures.cochat.ai/paper-figures/4beec5d0d8bc4db2ab6d963ef2acfa0f/the-m1-m2-spectrum-and-plasticity-of-malignant-pleural-effusion-macrophage-in-figure-1.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Macrophages have been shown to be plastic [334,335,336].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [335]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · cited 1×
“The TCGA database was selected and normalized as described previously [22, 24].”
Complex heatmaps reveal patterns and correlations in multidimensional genomic data
Gu, Z., Eils, R., & Schlesner, M. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw313 · Cited by 10,034 · cited 2×
“The heatmap of the gene expression data was generated using the R package “ComplexHeatmap” [25].”
MethodMacrophage activation and polarization: nomenclature and experimental guidelines
Murray, P. J., Allen, J. E., Biswas, S. K., Fisher, E. A., Gilroy, D. W., Goerdt, S., Gordon, S., Hamilton, J. A., Ivashkiv, L. B., Lawrence, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.008 · Cited by 6,337 · cited 1×
“Furthermore, interferon-gamma (IFN-γ)-stimulated macrophages, which were referred to as M1 macrophages or M (IFN-γ) cells [20], could decrease mouse lung cancer growth by decreasing the M2/M1 ratio in tumor microenvironments [21].”
BackgroundTumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Macrophage activation and polarization
Martinez, F. O. (2008) · Frontiers in Bioscience · doi:10.2741/2692 · Cited by 3,160
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756 · cited 1×
“PD-L1 on immune cells or tumor cells can interact with the co-inhibitory PD-1 receptor on T cells to attenuate T cell function [39], and PD-L1 expression can predict checkpoint inhibitor (anti-PD-L1) efficacy [40].”
BackgroundToward a Shared Vision for Cancer Genomic Data
Grossman, R. L., Heath, A. P., Ferretti, V., Varmus, H. E., Lowy, D. R., Kibbe, W. A., & Staudt, L. M. (2016) · New England Journal of Medicine · doi:10.1056/nejmp1607591 · Cited by 1,680
Macrophages, innate immunity and cancer: balance, tolerance, and diversity
Mantovani, A., & Sica, A. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.01.009 · Cited by 1,484
Lin, Y., Xu, J., & Lan, H. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0760-3 · Cited by 1,398 · cited 1×
“Macrophages around tumor cells (TAM) are associated with onco-immunity orchestration, tumor malignancy promotion, and metastasis [33].”
Backgroundβ‐glucan recognition by the innate immune system
Goodridge, H. S., Wolf, A. J., & Underhill, D. M. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00793.x · Cited by 688
Blank, C., Gajewski, T. F., & Mackensen, A. (2005) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-004-0593-x · Cited by 637
TAMeless traitors: macrophages in cancer progression and metastasis
Aras, S., & Zaidi, M. R. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.356 · Cited by 609
Ma, J., Liu, L., Che, G., Yu, N., Dai, F., & You, Z. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-112 · Cited by 437 · cited 3×
“Approximately 70% of TAMs were identified as the immunosuppressive M2 phenotype and reported to be polarized from M1 during tumor progression [12, 14].”
BackgroundChen, W.-J., Ho, C.-C., Chang, Y.-L., Chen, H.-Y., Lin, C.-A., Ling, T.-Y., Yu, S.-L., Yuan, S.-S., Louisa Chen, Y.-J., Lin, C.-Y., et al. (2014) · Nature Communications · doi:10.1038/ncomms4472 · Cited by 422
Self-citationOpposite Effects of M1 and M2 Macrophage Subtypes on Lung Cancer Progression
Yuan, A., Hsiao, Y.-J., Chen, H.-Y., Chen, H.-W., Ho, C.-C., Chen, Y.-Y., Liu, Y.-C., Hong, T.-H., Yu, S.-L., Chen, J. J. W., et al. (2015) · Scientific Reports · doi:10.1038/srep14273 · Cited by 352
Self-citationWang, F., Zhang, S., Jeon, R., Vuckovic, I., Jiang, X., Lerman, A., Folmes, C. D., Dzeja, P. D., & Herrmann, J. (2018) · eBioMedicine · doi:10.1016/j.ebiom.2018.02.009 · Cited by 339 · cited 1×
“To re-educate M2 macrophages toward the M1 type, previous reports have used human monocyte-derived macrophages or mouse bone marrow-cultured macrophages to identify that IFN-γ and β-glucan are involved in polarizing the M1-like phenotype and inhibiting the M2 polarization pathway [19, 36, 37].”
BackgroundFeller-Kopman, D., & Light, R. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1403503 · Cited by 329
Zhang, X., Zeng, Y., Qu, Q., Zhu, J., Liu, Z., Ning, W., Zeng, H., Zhang, N., Du, W., Chen, C., et al. (2017) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1161-7 · Cited by 316 · cited 1×
“1 3 signaling are involved in regulating PD-L1 expression [39, 42, 43].”
BackgroundHelm, O., Held‐Feindt, J., Grage‐Griebenow, E., Reiling, N., Ungefroren, H., Vogel, I., Krüger, U., Becker, T., Ebsen, M., Röcken, C., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28736 · Cited by 260 · cited 1×
“By contrast, our findings found that the MPE-Mφ may be different from the TAMs in lung tumor tissues and showed a dual tendency in their M1/M2 patterns, which is similar to the data for the TAMs in pancreatic ductal adenocarcinoma (PDAC) that expressed both M1 (HLA-DR, IL-1β and TNF-α) and M2 (CD163 and IL-10) markers…”
ResultRey-Giraud, F., Hafner, M., & Ries, C. H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042656 · Cited by 257
Create Elegant Data Visualisations Using the Grammar of Graphics [R package ggplot2 version 3.3.2]
Wickham, H., Chang, W., Henry, L., Pedersen, T. L., Takahashi, K., Wilke, C. O., Woo, K., Yutani, H., & Dunnington, D. (2020) · Cited by 235
Cancer‐promoting tumor‐associated macrophages: New vistas and open questions
Mantovani, A., Germano, G., Marchesi, F., Locatelli, M., & Biswas, S. K. (2011) · European Journal of Immunology · doi:10.1002/eji.201141894 · Cited by 207
Anti–PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment
Xiong, H., Mittman, S., Rodriguez, R., Moskalenko, M., Pacheco-Sanchez, P., Yang, Y., Nickles, D., & Cubas, R. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3208 · Cited by 197 · cited 1×
“Previous study showed that blockage of PD-L1 might promote TAMs into a more proinflammatory state [26].”
ResultKang, K., Park, S. H., Chen, J., Qiao, Y., Giannopoulou, E., Berg, K., Hanidu, A., Li, J., Nabozny, G., Kang, K., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.07.017 · Cited by 196 · cited 1×
“To re-educate M2 macrophages toward the M1 type, previous reports have used human monocyte-derived macrophages or mouse bone marrow-cultured macrophages to identify that IFN-γ and β-glucan are involved in polarizing the M1-like phenotype and inhibiting the M2 polarization pathway [19, 36, 37].”
BackgroundMei, J., Xiao, Z., Guo, C., Pu, Q., Ma, L., Liu, C., Lin, F., Liao, H., You, Z., & Liu, L. (2016) · Oncotarget · doi:10.18632/oncotarget.9079 · Cited by 196
Self-citationM1 Macrophages Induce PD-L1 Expression in Hepatocellular Carcinoma Cells Through IL-1β Signaling
Zong, Z., Zou, J., Mao, R., Ma, C., Li, N., Wang, J., Wang, X., Zhou, H., Zhang, L., & Shi, Y. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01643 · Cited by 196
Jin, Y., Li, P., & Wang, F. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.07.038 · Cited by 187
Malignant Pleural Effusion: Tumor–Host Interactions Unleashed
Stathopoulos, G. T., & Kalomenidis, I. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201203-0465pp · Cited by 186
Liu, M., Luo, F., Ding, C., Albeituni, S., Hu, X., Ma, Y., Cai, Y., McNally, L., Sanders, M. A., Jain, D., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1501158 · Cited by 165 · cited 3×
“β-glucan could repolarize mouse tissue macrophages and bone marrow-derived M2 macrophages into M1-like macrophages [19].”
BackgroundCXCL9: evidence and contradictions for its role in tumor progression
Ding, Q., Lu, P., Xia, Y., Ding, S., Fan, Y., Li, X., Han, P., Liu, J., Tian, D., & Liu, M. (2016) · Cancer Medicine · doi:10.1002/cam4.934 · Cited by 164
Morgensztern, D., Waqar, S., Subramanian, J., Trinkaus, K., & Govindan, R. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318267223a · Cited by 162
Allen, F., Bobanga, I., Rauhe, P., Barkauskas, D. S., Teich, N., Tong, C., Myers, J., & Huang, A. Y.-C. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1393598 · Cited by 159 · cited 1×
“Since CXCL9 and CCL3 are IFN-γ-related chemokines [30, 31], here we focused E D MPE-Mφ (M1-M2+)”
BackgroundMacrophages limit chemotherapy
Palma, M. D., & Lewis, C. E. (2011) · Nature · doi:10.1038/472303a · Cited by 138
Hedbrant, A., Erlandsson, A., Delbro, D. S., & Wijkander, J. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.2203 · Cited by 97
Li, Y., Wang, F., Wang, L., Huang, L. J., Wang, J., Zhang, B., & Zhang, Y. (2015) · Oncotarget · doi:10.18632/oncotarget.3547 · Cited by 95
Asciak, R., & Rahman, N. M. (2017) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2017.11.004 · Cited by 91
Li, L., Li, Y., Wang, L., Wang, F., Zhang, Z., Li, J., Yue, D., Chen, X., Yü, P., Huang, L. J., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30289 · Cited by 89 · cited 1×
“1 3 increase chemo-resistance and regulate immunity by reducing T cell activation, potentially through the interaction of programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) or through the release of immunosuppressive molecules, such as transforming growth factor-β (TGF-β) and interleukin (IL)…”
BackgroundModulation of the activation of Stat1 by the interferon-γ receptor complex
Krause, C. D., He, W., Kotenko, S. V., & Pestka, S. (2006) · Cell Research · doi:10.1038/sj.cr.7310015 · Cited by 60
CD163+CD14+ macrophages, a potential immune biomarker for malignant pleural effusion
Wang, F., Li, Y., Gao, Q., Huang, L. J., Wang, L., Wang, J., Wang, S., Zhang, B., & Zhang, Y. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1701-9 · Cited by 60
Liu, L., Ren, F., Fan, M., Mei, J., Wu, Y., Liu, C., Pu, Q., & You, Z. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s66302 · Cited by 47 · cited 1×
“Furthermore, interferon-gamma (IFN-γ)-stimulated macrophages, which were referred to as M1 macrophages or M (IFN-γ) cells [20], could decrease mouse lung cancer growth by decreasing the M2/M1 ratio in tumor microenvironments [21].”
BackgroundTseng, Y.-H., Ho, H., Lai, C., Luo, Y., Tseng, Y., Whang‐Peng, J., Lin, Y.-H., Chou, T., & Chen, Y.-M. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.10.034 · Cited by 41
Cardone, M., Dzutsev, A., Li, H., Riteau, N., Gerosa, F., Shenderov, K., Winkler-Pickett, R. T., Provezza, L., Riboldi, E., Leighty, R. M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114516 · Cited by 22
Review: Cell Dynamics in Malignant Pleural Effusions
Giarnieri, E., Bellipanni, G., Macaluso, M., Mancini, R., Holstein, A. C., Milanese, C., Giovagnoli, M. R., Giordano, A., & Russo, G. M. (2014) · Journal of Cellular Physiology · doi:10.1002/jcp.24806 · Cited by 21
Th1 and Th2 cytokine profiles in malignant pleural effusion.
Ghayumi, S. M. A., Mojtahedi, Z., & Fattahi, M. J. (2011) · PubMed · doi:10.22034/iji.2011.17026 · Cited by 12
Cited by
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Defects in Macrophage Reprogramming in Cancer Therapy: The Negative Impact of PD-L1/PD-1
Cai, H., Zhang, Y., Wang, J., & Gu, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.690869 · Cited by 140
Liu, Y., Wang, L., Song, Q., Ali, M., Crowe, W. N., Kucera, G. L., Hawkins, G. A., Söker, S., Thomas, K. W., Miller, L. D., et al. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-01032-w · Cited by 125
Zhang, S., Peng, W., Wang, H., Xiang, X., Ye, L., Wei, X., Wang, Z., Xue, Q., Chen, L., Yuan, S., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007441 · Cited by 104
“Cells were grown at 37°C in 5% CO 2 .”
Cancer: a mirrored room between tumor bulk and tumor microenvironment
Hernández-Camarero, P., López‐Ruiz, E., Marchal, J. A., & Perán, M. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02022-5 · Cited by 85
“For instance, it may seem interesting to establish the proportion of myofibroblasts-like CAFs compared with the total amount of CAFs [29] and/or to analyze TAMs establishing the proportion of M2/M1 [63] to determine the presence of the regenerative sub-microenvironment and thus predict the presence of CSCs.”
Background
Metadata
- Authors
- Wu, M.-F., Lin, C.-A., Yuan, T.-H., Yeh, H.-Y., Su, S.-F., Guo, C.-L., Chang, G.-C., Li, K.-C., Ho, C.-C., & Chen, H.-W.
- Affiliations
- National Taiwan University (TW)
- Soochow University (TW)
- Institute of Physics, Academia Sinica (TW)
- National Chung Hsing University (TW)
- University of California, Los Angeles (US)
- Corresponding author
- Ho, Chao-Chi
- Chen, Huei-Wen
- ORCID
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2020-11-11
- Volume
- 70
- Issue
- 5
- Pages
- 1435-1450
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC8053174
- OpenAlex
- W3105687100
- Cited by
- 48
- References
- 44
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 11 · 2023: 9 · 2022: 8 · 2021: 10
- FWCI
- 2.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Cancer Immunology Immunotherapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Ministry of Science and Technology, Taiwan (107-2627-M-002-001-, 107-2314-B-002-244-MY3, 108-2321-B-038-003, 108-3114-Y-001-002)
- Academia Sinica (AS-SUMMIT-108)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Stress, Anesthesia, and Immune Response
- Keywords
- malignant pleural effusion, tumor-associated macrophages, macrophage polarization, macrophage plasticity, lung adenocarcinoma, stage IV lung cancer, IL-1β, TGF-β1, macrophage repolarization, β-glucan, interferon-gamma, PD-L1, IL-10, prognostic signature, tumor immune evasion, overall survival
- MeSH terms
- Cell Plasticity, Cell Differentiation, Cells, Cultured, Humans, Lung Neoplasms, Macrophages, Neoplasm Staging, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Pleural Effusion, Malignant, Th1 Cells, Th2 Cells, Interleukin-1beta, Transforming Growth Factor beta1, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.